Febrile Neutropenia Overview

Save information for later
Sign Up

Learn About Febrile Neutropenia

What is the definition of Febrile Neutropenia?
Febrile neutropenia, also called neutropenic fever, is a condition in which an individual has a fever greater than or equal to 101° F for at least an hour and a low neutrophil count. This is usually due to an infection. Febrile neutropenia commonly occurs as a complication in patients with cancer who are undergoing chemotherapy.
What are the symptoms of Febrile Neutropenia?
Symptoms of febrile neutropenia include a fever greater than or equal to 101° F for at least an hour, a low neutrophil count, and signs and symptoms of an infection such as tenderness or pain.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Febrile Neutropenia?
Treatment for patients with febrile neutropenia depends on their overall condition. Treatments for febrile neutropenia include medications such as fluoroquinolone plus amoxicillin/clavulanate, clindamycin, cefepime, carbapenems, piperacillin, tazobactam, vancomycin, linezolid, daptomycin, polymyxin, colistin, tigecycline, triazole, trimethoprim-sulfamethoxazole, or a nucleoside reverse transcription inhibitor.
Who are the top Febrile Neutropenia Local Doctors?
Gary H. Lyman
Elite in Febrile Neutropenia
Dr. Gary H. Lyman
Oncology
Elite in Febrile Neutropenia
Dr. Gary H. Lyman
Oncology
825 Eastlake Ave E, 
Seattle, WA 
206-288-1000
Languages Spoken:
English
See accepted insurances

Gary Lyman is an Oncologist in Seattle, Washington. Dr. Lyman is rated as an Elite provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Febrile Neutropenia, Agranulocytosis, Venous Thromboembolism (VTE), and Breast Cancer.

Matti S. Aapro
Elite in Febrile Neutropenia
Matti S. Aapro
Elite in Febrile Neutropenia
Matti S. Aapro
Genolier, VD, CH 

Matti Aapro practices in Genolier, Switzerland. Aapro is rated as an Elite expert by MediFind in the treatment of Febrile Neutropenia. Their top areas of expertise are Febrile Neutropenia, Agranulocytosis, HER2 Negative Breast Cancer, and Breast Cancer.

 
 
 
 
Learn about our expert tiers
Learn More
Murat Akova
Elite in Febrile Neutropenia
Murat Akova
Elite in Febrile Neutropenia
Murat Akova
Ankara, TR 

Murat Akova practices in Ankara, Turkey. Mr. Akova is rated as an Elite expert by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Febrile Neutropenia, Agranulocytosis, Sepsis, Bone Marrow Transplant, and Splenectomy.

View All Doctors
What are the latest Febrile Neutropenia Clinical Trials?
Observational Study on the Efficacy of Empirical Antimicrobial Therapy in Febrile Neutropenia.
Observational Study on the Efficacy of Empirical Antimicrobial Therapy in Febrile Neutropenia.
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug

Summary: This single-arm, open-label clinical study evaluates the efficacy and safety of a standardized empirical anti-infective escalation protocol for patients with hematological malignancies complicated by febrile neutropenia. The treatment algorithm follows a sequential strategy: initial carbapenem monotherapy (2 days) → if ineffective, combination with vancomycin/linezolid (3 days) → if no response, e...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Exploratory Clinical Study of Efbemalenograstim Alfa-vuxw Injection for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
A Multicenter, Exploratory Clinical Study of Efbemalenograstim Alfa-vuxw Injection for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: Efbemalenograstim alfa for primary/secondary prevention in patients with solid tumors at high risk for febrile neutropenia (FN) or Intermediate risk of chemotherapy regimens associated with other risk factors in FN

View All Clinical Trials